Nurix Therapeutics (NRIX) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Nurix Therapeutics (NRIX) right now is Bexobrutideg pivotal path: The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. Revenue (Q1 FY2026, quarter ended Feb 28 2026) is ~$6.3 million. If that keeps playing out, the setup is favourable; the risk to it is as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. No one can predict where NRIX trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Nurix Therapeutics (NRIX) higher?
1. Bexobrutideg pivotal path.
The lead value driver is bexobrutideg, an oral BTK degrader positioned as potentially best-in-class in relapsed or refractory CLL. The pivotal Phase 2 DAYBreak CLL-201 study is intended to support an accelerated approval, and a confirmatory Phase 3 DAYBreak CLL-306 was slated to start around mid-2026. Positive, durable response data would be the single largest catalyst for the stock.
2. Roche collaboration.
In June 2026 Nurix announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology. The deal brings upfront and milestone payments plus shared development costs, validating the asset and extending Nurix's runway with non-dilutive capital while keeping the company exposed to commercial upside.
3. Partnered pipeline and platform.
Nurix earns collaboration revenue and future milestones from partnerships with Gilead Sciences (an IRAK4 degrader), Sanofi (a STAT6 degrader), and Pfizer. These deals help fund the platform and provide multiple shots on goal beyond the wholly owned CLL programs, though the largest partnered payments are contingent on downstream clinical and regulatory progress.
4. Immunology and pipeline expansion.
Beyond oncology, Nurix is pursuing autoimmune and inflammatory uses, including an IND target for a tablet formulation of bexobrutideg in immunology, plus additional degraders like NX-1607. Broadening from cancer into larger autoimmune markets is how the platform could scale, but these programs are earlier and years from potential revenue.
What could weigh on NRIX?
As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected pivotal path could sharply reduce the valuation. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.
Where NRIX trades today
A forecast starts from where the stock actually is. These are NRIX's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for NRIX as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a NRIX forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the NRIX guide and whether NRIX is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the NRIX outlook
The bottom line: what is driving Nurix Therapeutics (NRIX) is Bexobrutideg pivotal path, with revenue (q1 fy2026, quarter ended feb 28 2026) at ~$6.3 million. If that keeps playing out the setup is favourable; the risk is as a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. No one can predict the price, so treat any NRIX forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around NRIX with Walnut
Use Nurix Therapeutics as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Nurix Therapeutics (NRIX)?
+
No one can reliably predict where NRIX will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Nurix Therapeutics higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive NRIX higher?
+
The main growth drivers are Bexobrutideg pivotal path; Roche collaboration; Partnered pipeline and platform. Whether they play out is the real question, not a guaranteed path.
What are the risks to NRIX?
+
As a clinical-stage biotech, Nurix has no approved product and generates only modest collaboration revenue against large research spending, so it posts substantial net losses and depends on its cash balance and partner payments to keep funding trials. The value is concentrated in bexobrutideg, making the stock highly sensitive to a single set of trial readouts: disappointing efficacy or safety data, a regulatory setback, or a slower-than-expected pivotal path could sharply reduce the valuation. The company competes in a crowded targeted-protein-degradation field against Arvinas, Kymera, C4 Therapeutics, and large pharma, and against established BTK inhibitors already on the market. Future equity raises could dilute shareholders, and milestone payments from Roche, Gilead, Sanofi, and Pfizer are contingent and may never fully materialize. This is a high-risk, high-volatility name unsuitable for investors who need current income or capital preservation.
Will NRIX stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Nurix Therapeutics's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is NRIX a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the NRIX "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.